Literature DB >> 8133025

Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension.

G A Mensah1, T W Pappas, M J Koren, R J Ulin, J H Laragh, R B Devereux.   

Abstract

OBJECTIVE: To determine whether classification of the severity of hypertension according to the World Health Organization (WHO) system, which utilizes additional clinical and laboratory findings, is superior to classification by blood pressure level alone in predicting prognostically important cardiac structural abnormalities and the risk of subsequent complications in asymptomatic subjects.
DESIGN: Two-hundred and twenty adults with uncomplicated essential hypertension underwent baseline clinical evaluation and echocardiography; 88% were subsequently followed for a mean of 11.6 years.
SETTING: University hospital.
RESULTS: Left ventricular mass index and relative wall thickness were slightly greater in patients in the highest diastolic or systolic blood pressure stratum than in WHO stage II hypertensives, but these results were statistically non-significant. High peripheral resistance index was best identified by diastolic blood pressure level. Receiver operating characteristic curve analysis showed that all three methods had similar test performance in predicting abnormal left ventricular mass index, left ventricular geometry, relative wall thickness and peripheral resistance. During follow-up the proportion of patients who had a clinical event or died increased with increasing severity stratum in all three clinical classification systems, but the trends were statistically non-significant. Risk stratification by echocardiographic left ventricular mass index was most successful in identifying patients at very high and very low risk of subsequent morbid events and all-cause mortality.
CONCLUSION: Classification of hypertension severity by blood pressure level has similar, although limited, effectiveness at a lower cost than the WHO criteria in identifying patients with adverse cardiac changes and an impaired long-term prognosis. Echocardiographic measurement of left ventricular mass index was more successful than other classifications in predicting subsequent morbid events.

Entities:  

Mesh:

Year:  1993        PMID: 8133025     DOI: 10.1097/00004872-199312000-00016

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

Review 1.  Management of hypertension in patients with left ventricular hypertrophy.

Authors:  Cesare Cuspidi; Carla Sala; Alberto Zanchetti
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 2.  Hypertension, hypertrophy, heart failure.

Authors:  M G Nicholls
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

3.  Patterns of QT dispersion in athletic and hypertensive left ventricular hypertrophy.

Authors:  Laura Maria Lonati; Gaia Magnaghi; Caterina Bizzi; Gastone Leonetti
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

4.  The Impact of Left Ventricular Hypertrophy and Diastolic Dysfunction on Outcome in Intracerebral Hemorrhage Patients.

Authors:  Karen C Albright; Joshua M Burak; Tiffany R Chang; Aimee Aysenne; James E Siegler; Laurie Schluter; Sharyl R Martini; Amelia K Boehme; Sheryl Martin-Schild
Journal:  ISRN Stroke       Date:  2013

5.  Exercise-induced arterial hypertension - an independent factor for hypertrophy and a ticking clock for cardiac fatigue or atrial fibrillation in athletes?

Authors:  Roman Leischik; Norman Spelsberg; Hiltrud Niggemann; Birgit Dworrak; Klaus Tiroch
Journal:  F1000Res       Date:  2014-05-12

6.  Two Routes to Status, One Route to Health: Trait Dominance and Prestige Differentially Associate with Self-reported Stress and Health in Two US University Populations.

Authors:  Erik L Knight
Journal:  Adapt Human Behav Physiol       Date:  2022-08-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.